S. Giralt

648 total citations
18 papers, 486 citations indexed

About

S. Giralt is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, S. Giralt has authored 18 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in S. Giralt's work include Cancer Treatment and Pharmacology (5 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Multiple Myeloma Research and Treatments (4 papers). S. Giralt is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Multiple Myeloma Research and Treatments (4 papers). S. Giralt collaborates with scholars based in United States, United Kingdom and China. S. Giralt's co-authors include Issa F. Khouri, Richard E. Champlin, Naoto T. Ueno, Paolo Anderlini, Jeffrey J. Molldrem, Steven M. Kornblau, Avichai Shimoni, James Gajewski, James Gajewski and R. Champlin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

S. Giralt

17 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Giralt United States 5 325 218 95 93 75 18 486
SJ Forman United States 8 413 1.3× 116 0.5× 100 1.1× 22 0.2× 121 1.6× 8 517
X. Chai United States 11 189 0.6× 89 0.4× 64 0.7× 26 0.3× 60 0.8× 19 421
C. Reynolds United States 10 291 0.9× 166 0.8× 179 1.9× 20 0.2× 38 0.5× 23 543
Satyajit Kosuri United States 12 247 0.8× 150 0.7× 61 0.6× 25 0.3× 73 1.0× 47 420
Mónica Cabrero Spain 11 382 1.2× 93 0.4× 179 1.9× 29 0.3× 48 0.6× 33 558
Giuseppe Console Italy 15 475 1.5× 302 1.4× 90 0.9× 15 0.2× 60 0.8× 51 633
Johann Hermann Germany 6 186 0.6× 174 0.8× 96 1.0× 98 1.1× 101 1.3× 8 578
Edward Peres United States 10 337 1.0× 127 0.6× 165 1.7× 17 0.2× 72 1.0× 39 554
T. Demirer Türkiye 7 213 0.7× 116 0.5× 55 0.6× 13 0.1× 50 0.7× 7 346
Martin Söderberg Sweden 11 95 0.3× 282 1.3× 65 0.7× 105 1.1× 16 0.2× 18 419

Countries citing papers authored by S. Giralt

Since Specialization
Citations

This map shows the geographic impact of S. Giralt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Giralt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Giralt more than expected).

Fields of papers citing papers by S. Giralt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Giralt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Giralt. The network helps show where S. Giralt may publish in the future.

Co-authorship network of co-authors of S. Giralt

This figure shows the co-authorship network connecting the top 25 collaborators of S. Giralt. A scholar is included among the top collaborators of S. Giralt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Giralt. S. Giralt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
McCarthy, Phillip, Kouros Owzar, K. C. Anderson, et al.. (2010). Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.. Journal of Clinical Oncology. 28(15_suppl). 8017–8017. 55 indexed citations
3.
Miller, Jeffrey S., Jörg P. Ritz, W J Murphy, et al.. (2010). NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT:. 16(5). 1 indexed citations
4.
Popat, Uday, Rima M. Saliba, Chitra Hosing, et al.. (2009). Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation. Journal of Clinical Oncology. 27(15_suppl). e19507–e19507. 1 indexed citations
5.
Giralt, S., Kenneth F. Mangan, Richard T. Maziarz, et al.. (2008). Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT). Journal of Clinical Oncology. 26(15_suppl). 9617–9617. 4 indexed citations
6.
Giralt, S., et al.. (2008). Complete remission and survival in multiple myeloma. Journal of Clinical Oncology. 26(15_suppl). 8523–8523. 1 indexed citations
7.
Mobley, Gary M., et al.. (2006). Longitudinal assessment of inflammatory cytokines and symptom severity during first 100 days after allogeneic BMT for AML/MDS patients. Biology of Blood and Marrow Transplantation. 12(2). 23–23. 1 indexed citations
8.
Cohen, Marlene Z., Tito R. Mendoza, Ibrahima Gning, et al.. (2004). Social and cultural variables. Journal of Pain. 5(3). S104–S104. 1 indexed citations
9.
Lima, Marcos de, et al.. (2004). Be impressed with PRES. Biology of Blood and Marrow Transplantation. 10. 94–94. 1 indexed citations
10.
Cohen, Marlene Z., Tito R. Mendoza, J. Neumann, et al.. (2004). Longitudinal assessment of symptoms and quality of life: Differences by ablative and non-ablative blood and marrow transplantation. Journal of Clinical Oncology. 22(14_suppl). 6630–6630.
11.
Giralt, S., et al.. (2003). 191Barriers to second transplant for multiple myeloma in a randomized autologous tandem trial. Biology of Blood and Marrow Transplantation. 9(2). 120–120. 1 indexed citations
12.
Anderlini, Paolo, Sandra Acholonu, Grace‐Julia Okoroji, et al.. (2003). 26 Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin's disease (HD). Biology of Blood and Marrow Transplantation. 9(2). 71–71. 2 indexed citations
13.
14.
Champlin, Richard E., Issa F. Khouri, Avichai Shimoni, et al.. (2000). Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology. 111(1). 18–29. 157 indexed citations
15.
Hortobagyi, Gabriel N., Aman U. Buzdar, Richard L. Theriault, et al.. (2000). Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. JNCI Journal of the National Cancer Institute. 92(3). 225–233. 126 indexed citations
16.
Giralt, S., I. Khouri, & R. Champlin. (1999). Non Myeloablative “Mini Transplants”. Cancer treatment and research. 101. 97–108. 30 indexed citations
17.
Gopal, Ramesh, Chul S. Ha, S. Giralt, et al.. (1999). 2223 Comparison of two different total body irradiation (TBI) fractionation regimens with respect to acute and late pulmonary toxicity. International Journal of Radiation Oncology*Biology*Physics. 45(3). 392–393. 1 indexed citations
18.
Przepiorka, Donna, Cindy Ippoliti, Issa F. Khouri, et al.. (1996). Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation. Blood. 88(11). 4383–4389. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by SJ Forman Breakdown of academic impact, for papers by X. Chai Breakdown of academic impact, for papers by C. Reynolds Breakdown of academic impact, for papers by Satyajit Kosuri Breakdown of academic impact, for papers by Mónica Cabrero Breakdown of academic impact, for papers by Giuseppe Console Breakdown of academic impact, for papers by Johann Hermann Breakdown of academic impact, for papers by Edward Peres Breakdown of academic impact, for papers by T. Demirer Breakdown of academic impact, for papers by Martin Söderberg
Rankless by CCL
2026